Lenvaxen 10 mg (Lenvatinib) is an innovative oral medication designed to treat several types of advanced cancers, including thyroid cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). The active ingredient, Lenvatinib, is a multi-targeted tyrosine kinase inhibitor (TKI) that works by blocking the signals that promote the growth of cancer cells and the formation of blood vessels that supply…
Lenvaxen (Lenvatinib) is a powerful oral medication used to treat various types of cancer, including thyroid cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). The active ingredient in Lenvaxen is lapatinib, a tyrosine kinase inhibitor (TKI) that works by blocking multiple enzymes responsible for the growth and spread of cancer cells. This targeted approach helps slow down tumour growth,…
Lenvaxen 4mg (Lenvatinib) is a powerful, targeted cancer therapy specifically designed to treat advanced thyroid cancer, hepatocellular carcinoma (liver cancer), and renal cell carcinoma (kidney cancer). This innovative medication inhibits specific proteins that promote tumour growth and spread, slowing cancer progression. Lenvaxen 4mg has become a trusted choice for oncologists worldwide due to its efficacy in targeting multiple cancer types,…
Lorbrexen 100 mg (lorlatinib) is an innovative oral medication used to treat non-small cell lung cancer (NSCLC) in patients with a specific gene mutation known as ALK-positive . This cutting-edge therapy is designed to slow the progression of Cancer, offering hope for patients in the advanced stages of Treatment For Lung Cancer where other treatments may have failed. With Lorbrexen,…
Lorbrexen (Lorlatinib 100mg) is an innovative cancer therapy specifically designed to treat non-small cell lung cancer (NSCLC) that is positive for ALK (anaplastic lymphoma kinase) mutations. This targeted therapy is highly effective in managing advanced stages of ALK-positive NSCLC, especially in patients whose cancer has progressed despite prior treatment with other ALK inhibitors. Lorbrexen works by blocking the activity of…
Unlock a new avenue of hope in targeted cancer therapy with Mobocertinib 40 mg (Moboxen), a cutting-edge therapy specifically designed for patients with non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. With a focus on precision medicine, Mobocertinib offers a targeted approach that aims to inhibit tumor growth while minimizing side effects, making it a valuable option for those…
Niranib 100mg (Niraparib) is an advanced oral medication used for the maintenance treatment of ovarian, fallopian tube, and primary peritoneal cancers. It's part of a group of cancer treatments known as PARP inhibitors, which target and destroy cancer cells by preventing them from repairing their DNA. Niranib offers new hope for patients who are in remission following successful treatment with…
Obetix 5 mg (Obeticholic Acid) is a breakthrough medication designed to treat primary biliary cholangitis (PBC), a chronic liver disease that causes inflammation and damage to the bile ducts. Obeticholic acid, the active ingredient in Obetix, works by activating the farnesoid X receptor (FXR), a key regulator in bile acid metabolism. This helps reduce liver inflammation and damage, slowing the…
Olanib 50mg & 150mg (Olaparib) is a leading-edge oral medication used to treat various cancers, specifically ovarian, breast, prostate, and pancreatic cancers. This powerful drug belongs to a class of treatments known as PARP Inhibitor For Prostate Cancer (Poly ADP-Ribose Polymerase inhibitors). It is designed to stop cancer cells from repairing themselves, slowing tumour growth and enhancing survival rates.
Osicent 80mg (Osimertinib) is a groundbreaking medication designed for the treatment of non-small cell lung cancer (NSCLC) in patients with specific epidermal growth factor receptor (EGFR) mutations, including the resistant T790M mutation. As a third-generation EGFR inhibitor, Osicent 80mg offers a targeted approach that is proven to be effective in treating advanced and metastatic stages of NSCLC, particularly when the…
Osimert 80mg, containing the active ingredient Osimertinib, is a potent medication for treating non-small cell lung cancer (NSCLC). As a third-generation tyrosine kinase inhibitor (TKI), Osimertinib specifically targets and inhibits the activity of epidermal growth factor receptor (EGFR) mutations, including T790M resistance mutations, which are commonly associated with the progression of New Cancer Treatment For Lung Cancer. This targeted approach…
Palbocent 125 mg (Palbociclib) is an innovative oral medication used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib, the active ingredient in Palbocent, is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6, enzymes that play a crucial role in the growth and division of cancer cells. By blocking…
